Acute Promyelocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Promyelocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Promyelocytic Leukemia?
Acute promyelocytic leukemia (APL) is an aggressive type of acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow. This build up of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body. The signs and symptoms of APL include an increased risk to both bleed and form blood clots. Individuals may also experience excessive tiredness, pain in affected areas, loss of appetite, and weight loss. It is caused by a genetic change that is acquired over a person's lifetime, usually involving a translocation between chromosomes 15 and 17.
What are the alternative names for Acute Promyelocytic Leukemia?
  • Acute promyelocytic leukemia
  • AML M3
  • AML with t(15;17)(q22;q12);(PML/RARalpha) and variants
  • APML
  • Acute myeloblastic leukemia 3
  • Acute myeloblastic leukemia type 3
  • Acute myeloid leukemia with t(15;17)(q22;q12);(PML/RARalpha) and variants
Who are the top Acute Promyelocytic Leukemia Local Doctors?
Dr. Frank A. Knechtl
Hematology | Oncology
Dr. Frank A. Knechtl
Hematology | Oncology

Mclaren Oakland

1080 Harrington St, Suite 202, 
Mount Clemens, MI 
 (1.2 mi)
586-493-3440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Frank Knechtl is a Hematologist and an Oncologist in Mount Clemens, Michigan. Dr. Knechtl and is rated as an Experienced provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and RUNX1 Familial Platelet Disorder. Dr. Knechtl is currently accepting new patients.

Dr. Mohammed T. Masri
Hematology Oncology | Hematology | Oncology
Dr. Mohammed T. Masri
Hematology Oncology | Hematology | Oncology

Mclaren Oakland

1080 Harrington St, Suite 202, 
Mount Clemens, MI 
 (1.2 mi)
586-493-3440
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Mohammed Masri is a Hematologist Oncology specialist and a Hematologist in Mount Clemens, Michigan. Dr. Masri and is rated as an Experienced provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Lung Cancer, Familial Colorectal Cancer, Pleuropulmonary Blastoma, and Breast Cancer. Dr. Masri is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Malathy L. Kilaru
Hematology | Oncology
Dr. Malathy L. Kilaru
Hematology | Oncology

Henry Ford Health System

15855 19 Mile Rd, 
Clinton Township, MI 
 (4.4 mi)
586-263-2300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Malathy Kilaru is a Hematologist and an Oncologist in Clinton Township, Michigan. Dr. Kilaru and is rated as an Experienced provider by MediFind in the treatment of Acute Promyelocytic Leukemia. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Paget Disease of the Breast. Dr. Kilaru is currently accepting new patients.

View All Doctors
What are the latest Acute Promyelocytic Leukemia Clinical Trials?
Multi-center Phase II Prospective Study for the Treatment of Chidamide and Venetoclax in Patients With All-trans Retinoic Acid (ATRA) and Arsenic (As) Resistant Acute Promyelocytic Leukemia (APL)
Multi-center Phase II Prospective Study for the Treatment of Chidamide and Venetoclax in Patients With All-trans Retinoic Acid (ATRA) and Arsenic (As) Resistant Acute Promyelocytic Leukemia (APL)
Enrollment Status: Recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment. In our pre-clinical study, we found that targeting histone deacetylase inhibitor 3 (HDAC3)degraded PML-RARa oncoprotein and induced differentiation and apoptosis of RA and As resistant APL in...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Who is this study for: Child to adult patients with Recurrent or Refractory Solid Tumors or Acute Leukemia
Enrollment Status: Recruiting
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: PLX3397
Study Phase: Phase 1

Background: - Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center